Adapter Chimeric Antigen Receptor (AdCAR)-Engineered NK-92 Cells for the Multiplex Targeting of Bone Metastases

SIMPLE SUMMARY: Metastatic disease remains one of the biggest challenges for tumor therapy. The aim of our study was the preclinical evaluation of adapter chimeric antigen receptor (AdCAR)-engineered NK-92 cell efficacy as a possible treatment strategy for various types of bone metastatic cancers. W...

Descripción completa

Detalles Bibliográficos
Autores principales: Grote, Stefan, Traub, Frank, Mittelstaet, Joerg, Seitz, Christian, Kaiser, Andrew, Handgretinger, Rupert, Schleicher, Sabine
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7961358/
https://www.ncbi.nlm.nih.gov/pubmed/33807875
http://dx.doi.org/10.3390/cancers13051124

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7961358/
https://www.ncbi.nlm.nih.gov/pubmed/33807875
http://dx.doi.org/10.3390/cancers13051124

Ejemplares similares